Summary
The cytotoxicities of a new sarcosinamide analog of chloroethylnitrosourea (SarCNU) and of BCNU were examined in the glioma cell line SK-MG-1 in the presence or absence of excess concentrations of amino acids and sarcosinamide. The cytotoxicity of SarCNU, but not of BCNU, was significantly reduced in the presence of excess sarcosinamide. The stability of SarCNU was not significantly altered by increasing concentrations of sarcosinamide. In order to investigate the possibility that sarcosinamide inhibits the uptake of SarCNU, the transport of tritiated sarcosinamide was examined in SK-MG-1 cells. The uptake of 3H-sarcosinamide was inhibited by excess, unlabelled sarcosinamide and SarCNU but not by BCNU, glycine or sarcosine. These results suggest the existence of a carrier-mediated transport for sarcosinamide which can accomodate SarCNU in SK-MG-1 cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Prestayko AW, Cooke ST, Baker LH, Carter SK, Schein PS: Nitrosoureas: Current Status and New Developments. Academic Press, New York, pp 43–49, pp 181–336, 1981
Carter SK, Schabel Jr TM, Broler LE, Jonston TP: 1,3-Bis(2-chloroethyl)-1-nitrosourea and other nitrosoureas in cancer treatment: A review. Adv Cancer Res 16: 273–332, 1972
Suami T, Kato T, Takino H, Hisamatsu T: (2-chloroethyl) nitrosourea congeners of amino acid amides. J Med Chem 25:829–832, 1982
Panasci LC, Dufour M, Chevalier L, Isabel G, Lazarus P, McQuillan A, Arbit E, Brem S, Feindel W: Utilization of HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human gliomas compared with BCNU. Cancer Chemother Pharmacol 14: 156–159, 1985
Begleiter A, Lam HP, Goldenberg GJ: Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro. Cancer Res 37: 1022–1027, 1977
Vistica DT: Cytotoxicity as an indicator for transport mechanism: Evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 550: 309–317, 1979
Hamburger AW, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854, 1977
Von Hoff DD, Clark GM, Stugdill BJ: Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926–1931, 1983
Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon ET: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978
Meyskens F, Thompson SP, Moon TE: Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res 44: 271–277, 1984
Panasci LC, Green D, Nagourney R, Fox P, Schein DS: A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res 37: 2615–2618, 1977
Lazarus P, Panasci LC: Further studies of amino acid transport in murine P388 leukemia cells in vitro: Presence of system y+. Biochim Biophys Acta 856: 488–495, 1986
Yung WKA, Shapiro JR, Shapiro WR: Heterogenous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992–998, 1982
Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W: The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: Analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22: 137–140, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skalski, V., Feindel, W. & Panasci, L.C. The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport. J Neuro-Oncol 7, 189–193 (1989). https://doi.org/10.1007/BF00165103
Issue Date:
DOI: https://doi.org/10.1007/BF00165103